Axel Hauschild, MD, of University of Schleswig-Holstein, Kiel, Germany, reviews the clinical trial data for new treatments in melanoma presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. He highlights trials on combined BRAF and MEK inhibition versus BRAF inhibition alone, and immunotherapy drug combinations.
Allergy & Immunology
